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Abstract
Background: There is a need to establish more cell lines from breast tumors in contrast to immortalized cell lines
from metastatic effusions in order to represent the primary tumor and not principally metastatic biology of breast
cancer. This investigation describes the simultaneous isolation, characterization, growth and function of primary
mammary epithelial cells (MEC), mesenchymal cells (MES) and adipose derived stem cells (ADSC) from four normal
breasts, one inflammatory and one triple-negative ductal breast tumors.
Methods: A total of 17 cell lines were established and gene expression was analyzed for MEC and MES (n = 42) and
ADSC (n = 48) and MUC1, pan-KRT, CD90 and GATA-3 by immunofluorescence. DNA fingerprinting to track cell line
identity was performed between original primary tissues and isolates. Functional studies included ADSC differentiation,
tumor MES and MEC invasion co-cultured with ADSC-conditioned media (CM) and MES adhesion and growth on
3D-printed scaffolds.
Results: Comparative analysis showed higher gene expression of EPCAM, CD49f, CDH1 and KRTs for normal MEC lines;
MES lines e.g. Vimentin, CD10, ACTA2 and MMP9; and ADSC lines e.g. CD105, CD90, CDH2 and CDH11. Compared to the
mean of all four normal breast cell lines, both breast tumor cell lines demonstrated significantly lower ADSC marker
gene expression, but higher expression of mesenchymal and invasion gene markers like SNAI1 and MMP2. When
compared with four normal ADSC differentiated lineages, both tumor ADSC showed impaired osteogenic and
chondrogenic but enhanced adipogenic differentiation and endothelial-like structures, possibly due to high PDGFRB and
CD34. Addressing a functional role for overproduction of adipocytes, we initiated 3D-invasion studies including different
cell types from the same patient. CM from ADSC differentiating into adipocytes induced tumor MEC 3D-invasion via EMT
and amoeboid phenotypes. Normal MES breast cells adhered and proliferated on 3D-printed scaffolds containing 20
fibers, but not on 2.5D-printed scaffolds with single fiber layers, important for tissue engineering.
Conclusion: Expression analyses confirmed successful simultaneous cell isolations of three different phenotypes from
normal and tumor primary breast tissues. Our cell culture studies support that breast-tumor environment differentially
regulates tumor ADSC plasticity as well as cell invasion and demonstrates applications for regenerative medicine.
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Background
To this day, cell lines are pivotal for basic and clinical
research and decisive for the analysis of gene/protein ex-
pression, signal transduction, pharmacological and toxi-
cological experiments. Cell lines are the gold standard
for laboratory analyses due to their ease of handling,
self-replication, availability and homogenous nature [1].
This is true for breast cancer research, where a wealth of
published data is based upon cell lines, however, most
were derived from pleural effusion fluids of patients with
advanced-stage cancer [2]. The heterogeneity of breast
cancer, and the large variety of available breast cancer
cell lines require a careful choice of optimal cell lines for
specific experimentation [3]. In an analysis of 51 human
breast cancer cell lines, recurrent genome aberrations
and the resulting transcriptional changes mirrored those
of breast tumors, although other substantial differences
were detected [4]. Genotypical and phenotypical drift
after a range of subcultures of cell lines is also quite
frequent, thus contributing to discrepancies when com-
paring different studies [5]. Moreover, there are no cell
lines for male breast cancer, several rare histopathological
subtypes or uncommon chromosomal aberrations/muta-
tions of breast cancer [3, 4].
Normal human breast tissue is composed of glands
with a network of luminal epithelial, myoepithelial and
progenitor cells embedded in a stroma, consisting of
cells of mesenchymal lineage, adipocytes, fibroblasts, im-
mune, blood and endothelial cells, including the extra-
cellular matrix (ECM) essential for three-dimensional
microstructure [6]. Breast myoepithelial and luminal epi-
thelial cells stem from bipotent or other progenitor cells
where myoepithelial cells could also form directly from
the luminal lineage [7]. Interestingly, human breast
cancer cells are mainly of luminal epithelial lineage,
expressing mostly epithelial markers and the myoepithelial
cell is thought to even have tumor suppressing properties
[8]. According to newer cell classifications, human breast
tissue contains two diverse luminal and two basal epi-
thelial differentiation states that vary on the basis of
CD24, epithelial cell adhesion molecule (EPCAM) and
CD49f (Integrin alpha 6 or ITGA6) expression. It is
postulated that human breast cancer tissues also contain
these four cellular states, but in altered ratios compared to
normal tissues [9].
In addition to established cell lines the use of primary
cells isolated and grown in culture from human tissue
also provides a powerful and representative tool for
examining biological processes in vitro. In addition to
the frequently poor availability of primary human tissue,
the main barriers are the isolation procedure, cultivation
and characterization of primary cells. If all these properties
are in place, then cell functional studies can be performed
to address specific questions. For example, studies have
been performed to address the question of whether
primary tumor stromal cells significantly influence the
development of breast cancer [10]. Additionally, as the
complexity of breast tumor development is based upon
the fact that tumor and non-tumorigenic cells co-exist,
primary cultures could address why tumor cells have dif-
ferent clonal evolution and plasticity, and the contribution
of cancer stem and progenitor cells to the observed het-
erogeneity [11]. Interestingly, primary adipose-derived
stem cells (ADSC) influence MCF-7 cells by increasing
their proliferation when co-cultured [12, 13].
Primary cells are also currently implemented for tissue
engineering and regenerative studies [14]. For example,
to date, several types of breast augmentation for plastic
surgery and reconstruction are available: on the one
hand implants such as saline and silicone, on the other,
autologous fat transfer (AFT). Saline and silicone im-
plants do not support growth and vascularization and
have a possible risk of leakage, capsule fibrosis and infec-
tion, and need multiple changes. In AFT the patient’s
own fat tissue from other parts of the body is injected
into the breast, however, the procedure often needs sev-
eral rounds of grafting, and presently it is unknown how
non-breast-fat stem cells differentiate in the breast [15].
Although there are recent reports of increasing numbers
of ADSC injections into human breasts, there are no ad-
equate data on the potential carcinogenic effects to the
mammary epithelium. Taken together, to gain new in-
sights into normal and tumor cell development, studying
primary cell types in culture, or studying the interaction
between different cell types derived from normal and
tumor breast tissue, is currently possible [11].
Different isolation methods have been used to fraction-
ate breast epithelial cells from normal tissue [16, 17] and
tumor tissue for cultivation [18, 19]. These methods often
involve time-consuming and expensive isolation steps,
such as immunomagnetic or fluorescence-activated flow
sorting, facilitating the selection of one distinct cell type
from normal breast or tumor tissue or even from epithe-
lial cell cultures [17, 20, 21]. However, in most studies iso-
lation and characterization of only one specific cell type is
performed. Therefore, in this present study we simultan-
eously isolated three different cell types including mam-
mary epithelial (MEC), mesenchymal (MES) and ADSC
from normal or tumor breast tissues from the same pa-
tients. Cells were further characterized and compared for
the expression of specific epithelial, mesenchymal, endo-
thelial and stem cell markers. Studies were also performed
comparing ADSC differentiation into osteogenic, chron-
drogenic, adipogenic, and endothelial-like cells from nor-
mal and tumor breast tissues. Importantly, we addressed
the influence of conditioned media (CM) isolated from
normal and breast cancer ADSC during adipocyte differ-
entiation, on invasion of breast cancer MEC and MES
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cells in vitro. Last, we demonstrated an application involv-
ing primary breast cells for regenerative medicine.
Methods
Patients
Tissue samples were obtained from healthy women: normal
mammary cells (NORMA1-4) (from women with mean age
37 years) in medically indicated cases or surgery to the
breast. Samples were also obtained from two women with
breast cancer (mean age 59.5 years), one with invasive
inflammatory ductal carcinoma (IFDUC1) and one with
triple-negative ductal carcinoma, respectively (TRIDUC1)
(Table 1). Human tissue collection was approved by the
Ethics Committee of the University of Erlangen-Nürnberg
(Germany) (Ethics number 264_13B) in accordance with
the World Medical Association Declaration of Helsinki.
Informed consent was obtained from all patients.
Isolation of the epithelial (MEC) and mesenchymal (MES)
cell fractions
Up to 50 ml of fresh control or tumor breast tissue was
isolated and processed in a sterile manner. However, dif-
ferent amounts of tissues can be processed accordingly.
Tissues were washed extensively with 1 × PBS without
centrifugation, incubated in 1 × PBS with 1 × penicillin/
streptomycin (Life Technologies, Carlsbad, CA, USA)
(1:1 tissue (ml) to 1 × PBS) for 1 h at room temperature
(RT), cut into small pieces with removal of vascular
material and then digested with 0.5 × collagenase/hyal-
uronidase (StemCell Technologies, Vancouver, BC,
Canada) in DMEM plus 1 × penicillin/streptomycin en-
zymes according to Smith et al. and Emerman et al. [22,
23] but with some modifications. For 50 ml of tissue the
digestion period was 16 h at 37 °C with orbital shaking at
75 rpm. Following digestion, cells were diluted 1:1 with
1 × PBS and then centrifuged using 88 g for 30 s at RT.
The top fat layer (yellow) was discarded and the super-
natant containing single mesenchymal cells (S1) was
transferred into a 50-ml polypropylene tube and further
purified later as described below. The remaining pel-
let (P1) contained large epithelial duct-like clusters
(sometimes called organoids) derived from columnar
epithelium (extralobular) or a double layer of cuboidal epi-
thelium (intralobular) (Fig. 1a). P1 was further digested
with 0.01 % Trypsin (Gibco/Life Technologies) in 1 × PBS
for 30 minutes at 37 °C and 5 % CO2 on a rotator (Milte-
nyi Biotec GmbH, Bergisch-Gladbach, Germany) to fur-
ther dissociate epithelial cells and any glandular-attached
mesenchymal cells. For trypsin inactivation and further
fractionation, 5 ml of Epicult media + 5 % FCS (EMF +
5 %) (StemCell Technologies) was added, the cells resus-
pended and then centrifuged at 88 g for 30 s at RT. The
pellet fraction (P2), enriched of epithelial cells, was then
washed with EMF+ 5 % and centrifuged 217 g for 3 mi-
nutes at RT. In case of remaining residual undigested col-
lagen fibers, 10 ml EMF + 5 % was added to the pellet (P3)
and then passed through a 100-μm filter (BD, Franklin
Lakes, NJ, USA). The flow-through, mainly enriched with
single epithelial cells was then washed three times with
EMF + 5 % and centrifuged 217 g for 3 minutes at RT.
The pellet (P4) was resuspended in EMF + 5 % supple-
ment C (StemCell Technologies) and then seeded on pre-
viously coated collagen (collagen R from Serva
Electrophoresis GmbH, Heidelberg, Germany) tissue cul-
ture flasks (approximately 200,000 cells per 75 cm2 culture
dish). After 24 h the medium was changed to serum-free
EMF+ 1 × supplement C and 0.5 μg/ml hydrocortisone
(StemCell Technologies). Primary normal and tumor
mammary epithelial cells (MEC) were grown short-term
for up to 30 days without senescence (maximum eight cell
passages). Note that primary MEC from TRIDUC1 were
not isolated.
To obtain a purer mesenchymal cell fraction the super-
natant (S1) was passed through a 40-μm filter (BD) to re-
move any small epithelial duct-like glands and centrifuged
217 g for 3 minutes at RT. The remaining pellet (P5) con-
sisted of enriched mesenchymal cells and contaminating
red blood cells (RBCs). For RBC lysis, the pellet P5 was re-
suspended in 1 ml of 1 × PBS and 3 ml RBC-lysis solution
(0.8 % NH4Cl, 0.1 mM ethylenediaminetetraacetic acid
(EDTA), pH: 8.0) on a rotator (Miltenyi) for 12 minutes at
RT. The cells were then washed twice with 5 ml of EMF +
5 % at 217 g for 3 minutes at RT and the pellet (P6) was
resuspended in EMF+ 5 % plus 1 × supplement C and
Table 1 Tissues used for cell isolations from patients
Origin Side Tumor Age, years ER PR her2 Ki67 Type
TRIDUC1 breast left yes 73 neg neg neg 70 % basal cell
IFDUC1 breast right yes 46 pos pos 1+ 90 % ductal
NORMA1 breast left + right no 32
NORMA2 breast left + right no 23
NORMA3 breast right no 43
NORMA4 breast left no 50
ER estrogen receptor, PR progesterone receptor, her2 human epidermal growth factor receptor-2, TRIDUC1 triple-negative ductal carcinoma 1, IFDUC1 invasive
inflammatory ductal carcinoma 1, NORMA1-4 normal mammary cells 1-4
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0.5 μg/ml hydrocortisone. Approximately 200,000 cells
were seeded per 75-cm2 culture dish previously coated
with collagen R and incubated at 37 °C and 5 % CO2.
Primary normal and tumor mammary mesenchymal
cells (MES) were grown up to 30 days without senescence
(maximum eight cell passages) (Fig. 1a).
Isolation of adipose-derived stem cells (ADSC)
ADSC isolation was performed according to an adapted
protocol of Bunnell et al. [24]. Approximately 30 ml of
breast tissue was minced and digested with 0.1 % colla-
genase type I (Biochrom GmbH, Berlin, Germany) at
37 °C for 60–120 minutes. The enzyme digestion was
stopped with minimum essential medium (MEM) alpha
(Life Technologies) supplemented with 10 % FCS (FCS
superior, Biochrom) and centrifuged at 400 g for 10 mi-
nutes. The cell pellet was incubated in RBC lysis buffer
(17 mM tris-hydroxymethyl-aminomethane, 16 mM
NH4Cl) for 10 minutes at RT. After centrifuging at
300 g for 10 minutes, the cell pellet was resuspended in
Fig. 1 Isolation of mammary epithelial cells (MEC), mesenchymal cells (MES) and adipose-derived stem cells (ADSC) from human fat tissue and cell
type identification of normal mammary cells (NORMA)4. a Breast epithelial and mesenchymal cells were isolated from normal and tumor tissue
and ADSC were isolated from adipose tissue. Isolation of MEC and MES resulted in two critical fractions, a pellet (P1) and supernatant (S1), which
were the basis for the fractionation of epithelial (first row) and mesenchymal cells (second row), respectively. The P1 fraction was enriched with
large epithelial extralobular or intralobular duct-like glands and with further fractionation steps (P4) we observed enrichment of single epithelial
cells, whereas the P6 was enriched with mesenchymal cells. The pre-coating of the cell culture dishes with collagen enhanced the attachment
and proliferation of the epithelial cells, where cells grew exponentially up to 30 days as epithelial cell clusters. Immediately after isolation ADSC
were seeded in cell culture flasks (third row, first left). At 24 h after isolation (third row, middle) over 95 % of rounded cells became adherent. Cellular
morphology changed rapidly within the next few days to an elongated shape (third row, right). Scale bar 100 μm. b DNA fingerprinting used for cell
line identification. NORMA4 primary breast tissue and the isolated MEC and MES primary cell lines had 100 % congruence for all 21 short tandem
repeats (STRs). Lines on each graph represent STRs: blue, green and black indicate identities between the different samples
Weigand et al. Breast Cancer Research  (2016) 18:32 Page 4 of 20
MEM alpha with 10 % FCS and 1 × penicillin/strepto-
mycin (Biochrom GmbH), filtered through a 100-μm
and 70-μm mesh cell strainer (BD Biosciences, Franklin
Lakes, NJ, USA) and seeded in cell culture flasks. The
medium was changed two to three times a week. When
reaching 80–90 % confluency, ADSC were split in a ratio
1:3 using accutase (400–600 units/ml, Sigma-Aldrich
Corporation, St. Louis, MO, USA). Experiments were per-
formed at passage 4–7. For characterization, ADSC were
seeded on cell culture plates and differentiated into the
osteogenic, chondrogenic, adipogenic, and endothelial-like
lineages.
DNA fingerprinting of original breast tissue and derived
primary cell lines
For cell line identification we employed the analysis of
short tandem repeats (STRs), normally used for foren-
sic samples and paternity tests using the Powerplex®21
System (Promega, Corporation, Fitchburg, WI, USA).
The analysis included the amplification and detection
of all 13 combined DNA index system (CODIS) loci
(D3S1358, D5S818, D7S820, D8S1179, D13S317, D16S539,
D18S51, D21S11, CSF1PO, FGA, TH01, TPOX, vWA)
and six loci of Amelogenin, Penta D, Penta E, D1S1656,
D2S1338, D6S1043, D12S391 and D19S433. Genomic
DNA (500 pg) of the original tissue and different
established primary cell lines was isolated and purified.
The PCR was performed with the Powerplex®21 System
(Promega), the STR amplified, sequenced and visualized.
Immunocytochemistry
For characterization of isolated cells, immunocytochem-
ical staining was performed. Cells in passage 4–5 were
seeded in 8-chamber culture slides (BD). GATA binding
protein 3 (GATA-3) was visualized after fixation with
4 % formaldehyde and permeabilization with 0.25 %
Triton-X-100. For reduction of background staining
blocking with 10 % goat serum (Life technologies) was
performed for 30 minutes. Cells were incubated with a
mouse monoclonal GATA-3 antibody (1:100; IgG1,
Zytomed Systems, Berlin, Germany) for 1 h at RT and
Alexa Fluor® 488 goat anti-mouse IgG1 (γ1) antibody
(1:200; Life Technologies) for 1 h at RT. For CD90 stain-
ing, cells were fixed with 4 % paraformaldehyde. After
blocking with 5 % goat serum for 30 minutes, cells were
incubated with anti-CD90 (1:200, mouse monoclonal
(F15-42-1) IgG1, Acris antibodies, San Diego, CA, USA)
for 1 h at RT. For visualization Alexa Fluor® 594 goat
anti-mouse IgG1 (γ1) Antibody (1:200; Life Technolo-
gies) was used for 1 h at RT. After fixation of cells with
10 % formaldehyde and blocking with 5 % goat serum
for 30 minutes, cells were stained with a monoclonal
mouse anti-human cytokeratin (KRT) antibody (type 5,
6, 8, 17 and 19) (1:100; clone MNF116, Dako, Glostrup,
Denmark) for 1 h at RT. For visualization the secondary
antibody Alexa Fluor® 488 goat anti-mouse IgG1 (γ1)
Antibody (1:500; Life Technologies) was used for 30
minutes at RT.
Cells were fixed with 4 % paraformaldehyde for detec-
tion of the epithelial membrane antigen (EMA)/MUC1.
Background staining was reduced using 3 % H2O2. Stain-
ing was performed with a mouse monoclonal anti-EMA
IgG1 (1:50; clone GP1.4, Abcam PLC, Cambridge, UK) for
1 h at 37 °C using the LSAB System HRP (Dako). Coun-
terstaining was performed with hemalaun staining (Merck
Millipore, Billerica, MA, USA) and 4',6-diamidino-2-phe-
nylindole (DAPI) (1:1 000; Life Technologies). Evaluation
of staining was performed with a microscope and a digital
camera using computer-assisted image capture software
(Olympus IX83, cellSens Software, Olympus Corporation,
Tokio, Japan).
Quantification of cytokeratin-positive cell fraction
Cell fractions of NORMA1-3 in passage 4–5 were
seeded in 12-well chamber plates to calculate the per-
centage of KRT (type 5, 6, 8, 17 and 19)-positive cells
within the different cell isolates. After fixation and KRT
staining, counting of positive cells was performed auto-
matically using the Olympus cellSens Count & Measure
Software. The percentage of KRT-positive cells versus
total cell amount was calculated.
Real-time PCR
For RNA extraction cells in passage 4–5 were harvested
with accutase (400–600 units/ml, Sigma-Aldrich). RNA
of all probes was extracted using the RNeasy Mini Kit
with corresponding QIAshredder Homogenizer (Qiagen,
Hilden, Germany). RNA was reverse-transcribed into
cDNA with QuantiTect Reverse Transcription Kit with a
DNase I incubation (Qiagen). SsoAdvanced Universal
SYBR Green Supermix (Bio-Rad Laboratories, Hercules,
CA, USA) with a Light Cycler (Bio-Rad iCycler iQ5) was
used for quantitative real-time PCR. All kits were used ac-
cording to the manufacturers’ protocols. Samples were
tested as triplicates. Tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein, zeta (YWHAZ) was
used as a housekeeping gene. Data analysis was performed
using the 2-ΔΔCT method.
For CD34, control RNA human blood endothelial cells
(BEC) (PromoCell GmbH, Heidelberg, Germany) was
used. Control RNA from human peripheral blood cells
(PBC) was used for CD14, CD19, CD45 and HLA-DR.
Lysis of erythrocytes was performed by incubation 1:10
in lysis buffer for 5 minutes at RT. After washing and
centrifuging steps (300 g, 5 minutes) RNA was isolated
as described for cell isolates. Additional file 1 specifies
all primers used for real-time PCR.
Weigand et al. Breast Cancer Research  (2016) 18:32 Page 5 of 20
Differentiation of adipose-derived stem cells (ADSC) into
four different cell lineages
The differentiation potential of ADSC derived from normal
breast tissue (NORMA1-4) and tumor tissue (IFDUC1,
TRIDUC1) into osteogenic, chondrogenic, adipogenic, and
endothelial-like lineages was investigated. ADSC were
seeded in 24-well plates and cultivated in MEM alpha
supplemented with 10 % FCS for 3 days, and afterwards
were incubated using differentiation conditions.
For osteogenic differentiation ADSC were cultivated in
osteogenic induction medium consisting of MEM alpha
(Life Technologies) supplemented with 1 μM dexametha-
sone, 10 mM β-glycerophosphate and 50 μM ascorbic acid
(all from Sigma-Aldrich). After 28 days, cells were ana-
lyzed with Alizarin red (AppliChem GmbH, Darmstadt,
Germany) indicating osteogenic differentiation.
Chondrogenic differentiation of ADSC was studied
using cell pellets derived from a series of steps. First, a
cell suspension of 1.5 × 106 ADSC was diluted in 100 μl
2 % sodium alginate (Sigma-Aldrich) then the cell sus-
pension was pipetted and added as drops into a 0.1 M
CaCl2 solution and allowed to gel for 10 minutes at RT.
After washing with 0.15 M NaCl and PBS the cell pellets
were cultivated in hMSC chondrogenesis induction
medium (Provitro GmbH, Berlin, Germany) for 28 days.
Supplements essential for the chondrogenic induction
media included recombinant human insulin, human trans-
ferrin, sodium selenite (ITS), dexamethasone, ascorbic-
acid-2-phosphate, proline and the human growth factor
TGF-β3 (all from Provitro GmbH) and were added to
the basal medium. For detection of chondrogenic
differentiation Alcian blue staining (Alcian blue 8 GX,
Merck Millipore) was performed according to the
manufacturer’s protocol.
For differentiation into adipocytes, ADSC were cul-
tured in adipogenic induction medium (Provitro GmbH)
for 21 days. The medium was supplemented with FCS,
L-glutamine and HEPES, insulin, dexamethasone, indo-
methacine and 3-isobutyl-1-methyl-xanthine (all from
Provitro GmbH). Lipid vacuoles were detected by the
Oil Red O staining (Sigma-Aldrich) and counterstaining
was performed with hemalaun (Mayer's hemalaun solu-
tion, Merck KGaA, Darmstadt, Germany).
The endothelial differentiation potential of ADSC was
examined by performing a capillary-like tube formation
assay. Each well of a μ-slide (ibidi GmbH, Planegg,
Germany) was filled with 10 μl of Matrigel® (Growth
Factor Reduced Basement Membrane Matrix, Corning
Inc., Corning, New York, NY, USA), which was allowed
to polymerize for 30 minutes at 37 °C. Matrigel® con-
tains several growth factors like vascular endothelial
growth factor (VEGF) (1.0–1.5 ng/ml) and basic fibro-
blast growth factor (bFGF) (0.0–0.1 pg/ml) (Corning
Inc.: www.corning.com/media/worldwide/cls/documents/
CLS-DL-CC-026 DL.pdf) known to induce differentiation
if the tested cell type has endothelial potential [25]. ADSC
and human mammary epithelial cells (HMEC) were
seeded onto the wells in triplicates at a density of 1 ×
104 cells/well and cultured in 50 μl MEM alpha con-
taining 10 % FCS or mammary epithelial cell culture
medium (Provitro GmbH), respectively, for 5 h.
Evaluation of cells using the different staining proce-
dures was performed with a microscope and a digital
camera using computer-assisted image capture software
(Olympus IX83, cellSens Software, Olympus Corpor-
ation, Tokio, Japan). ImageJ (http://imagej.nih.gov) com-
puter software was used to measure colony area sizes
from differentiated cultures (osteogenic and chondro-
genic), or the total number of single cells containing
lipid droplets (adipogenic). The following parameters
were quantified for endothelial-like capillary structures:
1) total length of each capillary side structure; 2) the
area of all closed and non-closed capillary structures;
and 3) the total number of closed capillary structures
as loops using the Leica application suite V3 (Leica
Microsystems, Wetzlar, Germany).
Invasion analysis of breast cancer MEC and MES cells
under the influence of conditioned media from different
stages of ADSC adipocyte differentiation
Cell invasion assays were performed according to previ-
ous reports [26, 27]. Calf skin type I collagen G (Serva
Electrophoresis GmbH, Heidelberg, Germany) and rat
tail type I collagen R (Biochrom AG, Berlin, Germany)
were mixed at a ratio of 1:1 plus 0.1 volume of sodium
bicarbonate (23 mg/ml), 0.1 volume of 10 × DMEM,
and then the solution was neutralized with sodium
hydroxide. An aliquot of 0.6 ml was added to each 12-
well plate and then polymerized to obtain a 0.6-cm
collagen bed.
For cell culture 30,000 cells of IFDUC1 MEC (culti-
vated in mammary epithelial cell growth medium; Provi-
tro GmbH containing 10 ng/ml epidermal growth factor
(EGF), 0.5 μg/ml hydrocortisone, 5 μg/ml insulin and
4 % bovine pituitary extract (BPE)) or IFDUC1 MES
(cultivated in Epicult media plus 5 % charcoal-treated
serum (CTS) but with no supplement) were added to
the collagen beds and incubated for 1 h at 37 °C to allow
the cells to adhere. Conditioned media (CM) from
IFDUC1 or NORMA4 ADSC cells grown at different
stages of adipocyte differentiation (7, 14 and 21 days)
were then added in a series of dilutions (1:10, 1:20 and
1:30) to IFDUC1 MEC and MES cells on collagen. After
72 h all cells were fixed in 4 % paraformaldehyde. All in-
vaded cells were counted in >20 optical fields per well
and represented as number of cells per cm2 according to
previous reports [26, 27]. Criteria for mesenchymal and
amoeboid phenotypes were as previously reported [28].
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For the production of CM, ADSC-NORMA4 and
ADSC-IFDUC1 were seeded in 6-well plates and cultivated
in 3 ml MEM alpha + 10 % FCS until 80–90 % confluency.
Cells were then cultivated in adipogenic differentiation
medium supplemented with FCS, L-glutamine and HEPES,
insulin, dexamethasone, indomethacine and 3-isobutyl-1-
methyl-xanthine (all from Provitro GmbH). Two thirds of
the medium were changed every 2 days and the same
amount of CM was collected at time points 7, 14 and
21 days. To concentrate, CM was centrifuged in filter tubes
(Amicon® Ultra-15 Centrifugal Filter Devices, 3 K; Merck
KGaA, Darmstadt, Germany) at 4000 g for 30 minutes and
stored at −80 °C until further use.
Normal breast MES cell growth on a 3D printed scaffold
substrate and microscopy
Poly(ε-caprolactone) (PCL) scaffolds (20 μm× 20 μm
squares) were fabricated using melt electrospinning writ-
ing (MEW) as reported elsewhere [29]. The fibers were
spaced 150 μm apart and deposited at 90° to each other,
either as a single strand or layered 20 times. Prior to cell
seeding, the PCL scaffolds were pre-treated with ethanol
to remove air bubbles, hydrated with sterile deionized
water, incubated with 1 M NaOH for 30 minutes at RT
and washed several times with 1 × PBS. Each scaffold
was then incubated with 10 μg/ml fibronectin isolated
from human plasma (Roche Diagnostics, Rotkreuz,
Risch, Switzerland) in 1 × PBS for 1 h at RT in a 35-mm
tissue culture dish. A polydimethylsiloxane (PDMS) cast
ring was placed on top of the scaffold to secure it in
place: 250,000 primary fractioned MES cells (NORMA2)
were added to the scaffolds in EMF + 5 % plus 1 × sup-
plement C and 0.5 μg/ml hydrocortisone. Cells were
monitored every 3 days using phase contrast micros-
copy (Carl Zeiss AG, Oberkochen, Germany) to docu-
ment growth. After 18 days of growth when the cells
reached confluence the cells were fixed with 4 % para-
formaldehyde for 15 minutes at RT then washed once
with 1 × PBS. Cells were stained with the wheat germ
agglutinin Alexa Fluor 488 conjugate (Invitrogen/Life
technologies) specific for membranes and DRAQ5
(Biostatus Ltd., Shepshed, UK) for cell nuclei according
to manufactures’ instructions and then imaged using a
confocal laser scanning microscopy (Leica, SP5X). Laser
power was set to approximately 1.2 mW to avoid exten-
sive photobleaching. Alexa was detected with an Argon
laser at 488 nm and DRAQ5 with a He-Ne laser at
633 nm.
Statistics
Data are expressed as the mean ± standard error of the
mean. Statistical analysis was performed using SPSS
20.0 for Windows (SPSS Inc., Chicago, IL, USA). Results
were interpreted statistically using one-way analysis of
variance (ANOVA) and the Tukey honest significant dif-
ference (HSD) post-hoc test. The normal distribution
was confirmed using the Shapiro–Wilk test. For non-
normal data distributions, the non-parametric Kruskal–
Wallis test and the Mann–Whitney U test were used.
Results of gene expression in the individual patients
were interpreted statistically using the Mann–Whitney U
test. The level of statistical significance was set at p ≤0.05.
A p value ≤0.01 was considered highly significant. All
graphics were created using Microsoft Excel for Win-
dows 2010.
Results
Isolation of mammary epithelial (MEC) and mesenchymal
cells (MES) resulted in highly purified and stable primary
cell lines
Following the initial overnight digestion of control breast
or tumor tissue, cells were diluted and then centrifuged
at a low speed and time (88 g for 30 s). This critical low
speed and time resulted in two fractions, a pellet (P1)
and supernatant (S1), which were the basis for the frac-
tionation of epithelial and mesenchymal cells, respect-
ively. The P1 fraction was enriched with large epithelial
extralobular or intralobular duct-like clusters and with
further fractionation steps (P2 and especially P3 and P4)
we observed enrichment of single epithelial cells when
cultured on collagen-coated dishes (Fig. 1a). The pre-
coating of the cell culture dishes with collagen enhanced
the attachment and proliferation of the epithelial cells,
where cells grew exponentially up to and beyond
30 days as MEC clusters (Fig. 1a). Additionally, the epi-
thelial phenotype remained stable in EMF medium,
which is a serum-free, hormone enriched medium con-
taining hydrocortisone.
The fractionation of mesenchymal cells began with the
first supernatant (S1). Following several fractionation
steps the remaining cell pellet (P6) yielded single cells with
a mesenchymal phenotype when cultured on collagen-
coated culture dishes. The mesenchymal cells grew expo-
nentially up to and even beyond 30 days in the same EMF
medium as above, but containing 5 % FCS (Fig. 1a).
Therefore, from four different normal breast tissues and
two breast tumors we successfully isolated and established
MEC and MES primary cell lines.
Additionally, for future cell line identification, we im-
plemented a DNA fingerprinting technique amplifying
and sequencing 21 STR markers (Powerplex® 21 System)
(Fig. 1b). Following the analyses of the original normal
breast tissue (NORMA4) and the derived MEC and
MES primary cell lines a 100 % identical match was
found for all 21 STR markers. This result demonstrates
that DNA fingerprinting is a powerful tool for verifying
congruence with the original tissue, cell line identifica-
tion and proof of cell line purity.
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Immunocytochemical analysis demonstrated a variety of
different cell markers specific for cell types in normal and
tumor cells
To determine the purity of different cell types following
isolation and cell culturing we implemented a variety of
antibodies specific for different cell markers, which
could distinguish epithelial and mesenchymal origins, in-
cluding ADSC. For determination of epithelial cell origin,
we used a cytokeratin (KRT) antibody, which could detect
a variety of KRT types (5, 6, 8, 17 and 19). All MEC frac-
tions had almost 100 % positive KRT staining of the cyto-
plasm (Fig. 2a). In contrast, in the ADSC fractions
virtually no KRT-positive cells were found but on the
other hand some MES cell fractions demonstrated very
low percentages of KRT-positive cells (e.g., NORMA2
3.1 % and NORMA3 2.11 %). CD90 immunocytochemical
analysis was performed for mesenchymal cell identifica-
tion. Positive staining indicated high expression of the
cell-surface glycoprotein CD90 in the spindle-shaped
ADSC and MES fractions (Fig. 2b). In contrast, epithelial
cells from all fractions were >95 % CD90-negative. Only
NORMA1, had a few round-shaped cell colonies (about
10 %), which were sparsely positive. GATA-3, a member
of the zinc finger transcription factor family, which plays
an important role in cell proliferation and differentiation
of luminal glandular epithelial cells in mammary glands,
was visualized in epithelial cell isolates using immunocyto-
chemical analysis. Over 95 % of epithelial cells from all
fractions expressed this transcription factor in the nucleus;
however, GATA-3 was not detected in MES or ADSC
cultures (Fig. 2c). Additionally, we found that over
90 % of epithelial cells representing all fractions stained
positively for the epithelial membrane antigen (EMA)/
MUC1 (Fig. 3). In the MES fractions only a few colonies
(<5 %) were MUC1-positive and in the ADSC fraction
MUC1 was not detected (Fig. 3). Our findings support
that each isolated and established cell line represents
>95 % similarity with cell-type-specific markers.
Fig. 2 Immunofluorescence staining of cell isolates. a Immunofluorescence hybridization demonstrated the epithelial origin of cell isolates incubated
with a pan-cytokeratin (KRT) type 5, 6, 8, 17 and 19 antibody. All epithelial cell fractions had positive localization of the cytoplasm (green). In contrast, in
the mesenchymal cell fraction very few positive cells were identified (e.g., normal mammary cells (NORMA)3). Adipose-derived stem cells (ADSC) were
KRT-negative. Nuclei were identified using 4',6-diamidino-2-phenylindole (DAPI) (blue). b CD90 immunocytochemical analysis was performed for
mesenchymal cell characterization. Positive localization was visible in ADSC and mammary mesenchymal cell (MES) fractions (red). In contrast,
epithelial cells were largely CD90-negative. Only in NORMA1 were a few rounded-shape cell colonies sparsely positive. Counterstaining was performed
using DAPI (blue). c GATA-3 was visualized in epithelial cell isolates using immunocytochemical analysis. Almost all cells in the epithelial cell fraction
expressed this transcription factor but it was not detected either in the MES or ADSC fraction (green). Counterstaining was performed using DAPI (blue).
Overlay demonstrates co-localized cells with turquoise nuclei. Bar 100 μm
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Characterization of ADSC, MEC and MES primary cell lines
using real-time PCR
Following our cell-type protein expression analyses de-
scribed above, we then profiled all primary cell lines
(NORMA1-4) using real-time PCR for 48 genes to help
further classify specific cell phenotypes. Compared to all
MEC and MES fractions, ADSC fractions had increased
expression of the cell surface markers CD105, CD73,
CD90, CD36 and CD29, where CD105, CD90 and CD36
expression were significantly higher (Fig. 4a, Additional
file 2a-d). The intermediate filament protein vimentin
(VIM), a well-known marker for mesenchymal cells,
clearly demonstrated significantly higher levels of gene
expression in MES when compared to MEC, but was
not significantly different to ADSC (Fig. 4a, Additional
file 2a-d). Furthermore, N-cadherin (CDH2) and CDH11,
additional markers of the mesenchymal phenotype, were
strongly expressed in ADSC compared to both MEC and
MES primary cell lines (Fig. 4b, Additional file 3a-d).
Finally, there was greater expression of the fibroblast mes-
enchymal marker S100A4, which is associated with a more
differentiated state, in both MES and ADSC compared to
MEC (Fig. 4b, Additional file 3a-d). Expression of a range
of typical epithelial cell markers was investigated in all pri-
mary cell lines using real-time PCR (Fig. 4c, Additional file
4a-d). As expected, MEC expressed epithelial cell markers
such as MUC1, EPCAM, E-cadherin (CDH1), P-cadherin
(CDH3) and six cytokeratin genes (KRT5/7/8/14/18/19),
supporting a general epithelial phenotype. However, ex-
pression of some markers, such asMUC1 and the cytoker-
atin KRT8 and KRT19 genes expressed on luminal cells,
varied between MES primary cell lines (Fig. 4c, Additional
file 4a-d). Significantly greater expression of RAC1, known
as a regulator for various cellular functions including dif-
ferentiation of mammary epithelia, was observed in ADSC
and MES compared to MEC, supporting different func-
tions for this gene among primary breast cells (Fig. 4c).
We also examined other genes in all primary cell lines
(NORMA1-4) derived from patients, which correlated
with proliferation, stem cells and muscle-specific genes
(Fig. 4c, Additional file 4a-d). For example, although all
primary cell lines expressed the proliferation marker
MKI67, there was significantly greater expression in MEC
compared to the other primary cell lines. Additionally,
there was significantly greater expression of the epithelial
stem cell markers CD24 and CD49f in MEC compared to
MES and ADSC. Finally, there was significantly lower ex-
pression of markers of basal myoepithelial mammary cells,
including calponin (CNN1), alpha smooth muscle actin
(ACTA2) and CD10, in all MEC fractions, supporting
there being no significant myoepithelial component when
compared to ADSC and/or MES cell fractions. In contrast,
our results point to a positive association between muscle
characteristics (CNN1 and ACTA2) and ADSC or MES.
Exploring the expression of key genes involved in
invasion and signaling pathways, the matrix metallopro-
tease (MMP) 2 gene, specific for digestion of the ECM,
was significantly greater in ADSC, when compared to
MEC, however, there was no difference to MES (Fig. 4b,
Additional file 3a-d). In contrast, expression of MMP9
was significantly greater in MES when compared to ADSC













Fig. 3 Epithelial membrane antigen (EMA)/MUC1 immunocytochemical staining of cell isolates. Mammary epithelial cells (MEC), adipose derived
stem cells (ADSC) and mesenchymal cells (MES) primary cell lines all from the same patients (three normal and one breast-tumor primary cell
lines) are indicated above. MEC had positive protein expression for EMA/MUC1 (brown). ADSC were negative for MUC1 protein expression.
In the MES very few small colonies were identified as MUC1-positive. Bar 100 μm. IFDUC invasive inflammatory ductal carcinoma
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low expression levels of SNAI1, a transcriptional repressor
of CDH1 expression and a marker of epithelial to mesen-
chymal transition (EMT), were associated with each MEC
primary cell line when compared to the MES and ADSC.
For signaling pathways, although the amoeboid cell shape
indicator Rho GTPase activating protein 22 (ARHGAP22)
gene was differentially expressed, no significant differences
were observed between primary cell lines.
Last, we analyzed the presence of hematopoietic cell
markers in all primary cell lines, and endothelial cell
marker genes specifically in ADSC lines where, for ex-
ample, CD34 is associated with stem cells. We observed
that there was significantly lower expression of CD14,
CD19, CD45 and HLA-DR, with the exception of CD34,
on all representative cell types when compared to a
positive control consisting of PBC or BEC (Fig. 4a,
Additional file 2g-j). These results demonstrate no
contamination of peripheral blood cells in the primary
cell lines. While there was significantly lower expression
of CD34 in MEC and MES normal and tumor primary cell
lines compared to blood cells, interestingly, ADSC CD34
expression was in general significantly greater among
primary cell lines (Fig 4a). Although the expression of
six endothelial differentiation marker genes (PECAM1,
vWF, FLT1, FLT4, KDR, CDH5) was significantly lower in
normal and tumor ADSC, there was significantly greater
expression of PDGFRB in ADSC when compared to BEC
and NORMA1 MEC cells (Fig. 4d). These results support
the sharing of the progenitor CD34 and PDGFRB expres-
sion found in endothelial cells and pericytes, which is ne-
cessary for angiogenesis [30, 31], in both normal and
tumor ADSC.
Characterization and comparison of breast tumor primary
cell lines (IFDUC1, TRIDUC1) with NORMA1-4 breast
primary cell lines
We found significant differences when comparing the
gene expression of cell fractions isolated from the tu-
mors TRIDUC1 or IFDUC1 with the mean of each gene
from normal breast tissues (NORMA1-4). For example,
on gene expression analysis there were very low signifi-
cant levels of all ADSC stem cell markers in ADSC of
TRIDUC1, and only 0.5-fold to 1.0-fold of markers in





Fig. 4 Gene expression of cell isolates. Real time PCR results show gene expression (n = 48) genes, including a house keeping gene after
comparison to the mean expression of all normal (NORMA1-4) respective MEC, MES or ADSC primary cell lines. a Expression of positive stem cell
markers CD105, CD73, CD90, CD36, CD29, CD44 and of vimentin (VIM) (ADSC=1) and hematopoietic markers CD14, CD19, CD34, CD45, HLA-DR are
shown (PBC/BEC=1). b Panel shows invasion and EMT marker genes, MMP2, MMP9 and SNAI1, the fibroblast mesenchymal marker S100A4 and
N-cadherin (CDH2) and CDH11, markers of the mesenchymal phenotype (MES=1). c Epithelial cell markers (MEC=1) compared to ADSC and MES.
Specific markers include epithelial stem cell markers CD24 and CD49f and markers of basal myoepithelial mammary cells (ACTA1, CNN1, ACTA2,
CD10). d Six endothelial marker genes analyzed were PECAM1, VWF, FLT1, KDR, FLT4, CDH5 and PDGFRB (BEC=1). Significant values compared with
BEC (*, **) or MEC NORMA1 (#, ##). (*,# p ≤ 0.05, **,## p ≤ 0.01) (ADSC = adipose derived stem cells, BEC = blood endothelial cells MEC = mammary
epithelial cells, MES = mesenchymal cells, PBC = peripheral blood cells)
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(Fig. 5a, Additional file 2e, f ). Interestingly, the stem cell
marker CD36 was expressed approximately 7.0-fold
higher in both the ADSC NORMA1-4 and the ADSC
IFDUC1, when compared to ADSC TRIDUC1 cells
(Fig. 5a, Additional file 2e, f ). Considering mesenchymal
or muscle specific marker genes, there was generally
greater expression for both tumor MES primary cell
lines when compared to NORMA1-4 MES cell lines
(Fig. 5b, Additional files 2, 3 and 4). For example, VIM
expression in MES IFDUC1 and TRIDUC1 cells demon-
strated 8.0-fold to 12.0-fold higher levels, when com-
pared to MES cells of NORMA1-4. Significantly higher
levels of the CDH2 and CDH11 mesenchymal genes
were observed, especially for IFDUC1 MES cells com-
pared to NORMA1-4 primary breast cell lines (Fig. 5b).
Both EMT marker genes, SNAI1 and ARHGAP22, were
expressed 17.4-fold and 12.4-fold higher in IFDUC1 MES
than NORMA1-4 MES, respectively, suggesting an active
invasive state (Fig. 5b). Further support for activated inva-
sion in tumor MES was indicated with MMP2 gene ex-
pression, which was over 8.5-fold higher for MES of
IFDUC1 compared to NORMA1-4 MES (Fig. 5b).
On comparing the tumor MEC primary cell line from
IFDUC1 with all NORMA1-4 cell lines, only minor dif-
ferences could be detected in general. While KRT18/19,
MUC1 and CNN1 were expressed to a lower extent in
MEC IFDUC1, there was significantly greater expression
of CD34, CD45, CD24, CD49f, CDH1 CDH3 and KRT5
when compared to NORMA1-4 MEC primary cell lines
(Fig. 5c, d, Additional file 4e).
Last, we analyzed the expression of novel breast cancer
targetsMCAM/CD146 and SOD1 in the cell lines [32, 33].
Interestingly, there was significantly greater expression




Fig. 5 Gene expression results of cells derived from cancer tissue compared to normal breast tissue. Gene expression comparison of adipose-
derived stem cell (ADSC), mesenchymal cell (MES) and mammary epithelial cell (MEC) primary cell lines of invasive inflammatory ductal carcinoma
(IFDUC1) and triple-negative ductal carcinoma (TRIDUC1) with the representative primary cell lines of normal mammary cells (NORMA)1-4. Real-
time PCR results were calculated for 2-ΔΔct (Y-axes) for the marker genes of ADSC (a), MES (b) and MEC (c, d). For MEC primary cell lines only
IFDUC1 was compared with NORMA1-4 (MEC mean). e Gene expression levels of two novel breast cancer markers, CD146/MCAM and SOD1 2-ΔΔct
(Y-axes) comparing both breast cancer cell lines with NORMA1-4. For each cell line the NORMA1-4 values were averaged
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NORMA1-4. Comparing MES NORMA1-4 with MES
TRIDUC1 we detected a significant increase in expression
of SOD1 in cancer cells (Fig. 5e).
Culture of isolated ADSC resulted in differentiation of
four separate cell lineages
To test the multipotent nature of ADSC we performed
a variety of cell culture studies following fractionation.
Initially, after isolation and seeding we observed that
the cells were round-shaped and then became fully
attached within 24 h. In approximately 1 week of culturing
the cells grew exponentially and had a typical and
homogenous mesenchymal-like appearance (Fig. 1a).
To verify the multipotency of ADSC we performed
functional analyses, where normal and tumor ADSC
were differentiated into osteogenic, chondrogenic, adipo-
genic, and endothelial-like lineages (Fig. 6). NORMA1-4
ADSC differentiated similarly into all four cell lineages
thus, were comparable (Fig. 6a-r and data not shown).
As an example, NORMA4 had strong osteogenic differen-
tiation as demonstrated with Alizarin red staining detect-
ing extracellular calcium deposits (Fig. 6a). Alcian blue
staining revealed the presence of glycosaminoglycan after
chondrogenic differentiation (Fig. 6b, c). Adipogenic dif-
ferentiation was shown by staining of lipid droplets with
Oil Red O (Fig. 6d). Last, negative control groups for all of
the above were cultivated in standard culture medium
alone and there was no positive staining for all lineages
(Fig. 6s-v).
It is well-known that endothelial cells form unique
branching capillary-like structures on Matrigel®, where
one hallmark is the presence of single mesenchymal
spindle cells that stretch and line the capillary lumen
[25, 34]. Interestingly, within 5 h after the seeding of
normal breast ADSC onto polymerized Matrigel® beds,
endothelial-like capillary structures were noted, thus
supporting that there was differentiation towards angiogen-
esis (Fig. 6e, f). Although normal control breast MEC
formed web-like colonies (Fig. 6w, x), only ADSC dem-
onstrated capillary structures consisting of single
mesenchymal-like cells bordering the capillary lumen
(Fig. 6f ). Therefore, normal breast MEC cells demon-
strated cell-cell adherence properties but represented a
negative control in endothelial-like characteristics.
Taken together, primary ADSC from normal breast tis-
sues differentiated in culture into four separate cellular
lineages and thus, retained their stem cell nature after
isolation.
Additionally, we performed differentiation studies














































Fig. 6 Multipotent adipose-derived stem cell (ADSC) differentiation into four different cell lineages. For verifying the multipotency of isolated ADSC
from normal and tumor breast tissue, cells were differentiated into the osteogenic, chondrogenic, adipogenic and endothelial cell lineages. Osteogenic
differentiation was demonstrated by Alizarin red staining (a, g, m), chondrogenic differentiation by Alcian blue staining (b, c, h, i, n, o, t, u), adipogenic
differentiation by Oil Red O staining (d, j, p) and endothelial-like capillary tube structures (e, f, k, l, q, r). Negative control groups cultivated in standard
cell culture medium, but without additional supplements, showed no positive staining (s-v). Normal (NORMA)4 mammary epithelial cells
represented a negative control for endothelial-like tube assays (w, x). Bar = 200 μm. IFDUC invasive inflammatory ductal carcinoma, TRIDUC
triple-negative ductal carcinoma
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and TRIDUC1. Osteogenic differentiation was impaired
for both tumor cell lines compared to NORMA4 (56.9 %
for IFDUC1 and 36.1 % for TRIDUC1 compared to
NORMA4 set to 100 %) (Fig. 6a, g, m). Chondrogenic
differentiation was also reduced for both tumor ADSC
(NORMA4 was 12.85-fold higher than negative control
set to 1; IFDUC1 was 4.42-fold and TRIDUC1 4.38-fold
higher than the negative control) (Fig. 6b, c, h, i, n, o).
On the other hand, for adipogenic differentiation of
tumor, ADSC was higher compared to NORMA4 set to
1 (IFDUC1 1.52-fold; TRIDUC1 1.38-fold) (Fig. 6d, j, p).
We interpret our findings that the tumor environment is
negatively influencing tumor ADSC to differentiate into
osteogenic and chondrogenic lineages but positively influ-
encing tumor ADSC towards adipocyte differentiation.
Interestingly, both breast cancer ADSC also differenti-
ated into classical endothelial-like capillary structures
similar to normal breast ADSC (Fig. 6e, f, k, l, q, r).
However, on measuring different endothelial-like struc-
tural characteristics there were significant differences be-
tween tube length and area when comparing breast cancer
and normal ADSC (Additional file 5a-c). Tubes were sig-
nificantly longer in TRIDUC1 compared to NORMA4,
suggesting increased cellular physical strength. Although
the total capillary loop formation did not differ signifi-
cantly between breast cancer and normal ADSC, the
endothelial-like area of complete and non-complete
capillary structures was significantly smaller for both
TRIDUC1 and IFDUC1 when compared to NORMA4,
indicating more complete endothelial-like differentiation
for the tumor ADSCs.
Conditioned media from tumor and normal ADSC
differentiating into adipocytes induced an EMT with
increased 3D invasion of breast cancer MEC
We designed cell culture studies to address a possible
tumor function for the overproduction of breast adipo-
cytes derived from tumor ADSC compared to normal
breast ADSC (Fig. 6 d, j, p; Fig. 7). Our approach in-
volved isolating CM from ADSC-IFDUC1 and ADSC-
NORMA4 during adipocyte differentiation at three time
points over 21 days. IFDUC1-MEC and IFDUC1-MES
were then incubated with the above CM to test the
influence on invasion using 3D collagen matrices for
72 h. CM from all adipocyte differentiation stages sig-
nificantly increased the invasion of IFDUC1-MEC,
where CM at week 3 induced the greatest invasion
(Fig. 7a). Additionally, IFDUC1-MEC invasion was aug-
mented with CM from differentiated IFDUC1-ADSC
compared to NORMA4-ADSC (Fig. 7a). Thus, CM from
both breast tumor and normal differentiating ADSC
significantly induced invasion of tumor MEC cells,
supporting a role of critical adipokine factors. Importantly,
all collagen-invaded IFDUC1-MEC consisted mainly of a
mesenchymal phenotype and fewer amoeboid phenotypes,
supporting that there is enhancement of an EMT or an
epithelial to amoeboid transition (Fig. 7b, c). In contrast,
IFDUC1-MES cells showed no significant increase of inva-
sion in the presence of CM, but demonstrated high num-
bers of invaded mesenchymal cells, indicating innate high
invasiveness of breast tumor MES (Fig. 7d, e).
Multiple PCL fiber scaffolds support adhesion and
initiation of cellular growth
Presently, there is a need to study the growth of primary
cells on biomaterials applicable for tissue regeneration,
for example, breast reconstruction. We therefore studied
the growth properties of primary normal breast cells on
fine, 3D-printed PCL scaffold substrates (Fig. 8a, b) with
fiber diameters of 14 ± 1 μm. A 2.5D scaffold consisting
of only a single strand layer (PCL-1) was compared to a
3D scaffold with 20 alternating fiber layers (PCL-20) for
growth with primary NORMA2 MES cells. Following the
seeding of MES cells, we observed that cellular growth ini-
tiated from the fiber frame within 6 days. Interestingly,
these cells appeared to represent a bridge facilitating fur-
ther proliferation toward the scaffold center. After 18 days
increased cellular confluency of >90 % was observed
throughout the 3D scaffold with PCL-20 (Fig. 8a, b), but
in contrast no cell growth occurred with PCL-1 (Fig. 8a).
Our results indicate how cell adhesion and proliferation is
affected through the use of 3D scaffold structures.
Discussion
In 1958 an epithelial cell line called BT-20/HTB-19 was
established directly from a solid invasive ductal breast
carcinoma [35]. Introduced later were many other breast
cancer cell lines [4], of which two of the best known are
MCF-7 (HTB-22) and MDA-MB231 (HTB-26). However,
most of these cell lines, including MCF-7 and MDA-
MB231, did not directly originate from the primary tumor
(Table 2). MCF-7 was generated from a pleural effusion
more than 3 years after mastectomy and radiation/hor-
mone therapy; MDA-MB231 was also initiated from a
pleural effusion 4 years after mastectomy [36, 37].
In addition to the question of cell comparability between
primary tumors and pleural effusions, and the reproduci-
bility of tumor-cell-related gene/protein and signaling,
many cell lines are contaminated; e.g., human cervix car-
cinoma HeLa cells with rodent cells or other misidentified
cells [38, 39]. Therefore, it is essential to implement tests
to genomically verify the identity of cell lines [39] like
DNA fingerprinting, which we demonstrated for one pa-
tient’s primary tissue and isolated cell lines.
Based upon several publications four major cell types
within normal human breast tissue have been assigned
using both gene and protein expression. This profile
is the following: 1) luminal 1 epithelial cells (EPCAM
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high/CD49f-/CD24+/KRT8, 18 high/KRT14-/ACTA1-
(alpha skeletal muscle actin)/VIM low); 2) luminal 2 epi-
thelial cells (EPCAM high/CD49f+/CD24+/KRT8, 18
high/KRT14-/ACTA1-/VIM+); 3) basal epithelial cells
(EPCAM low/CD49f+/CD24-/KRT8, 18 low/KRT14
+/ACTA1 high/VIM high) and 4) mesenchymal cells
(EPCAM-/CD49f+/CD24-/KRT8, 18 low/KRT14 low/
ACTA1 low/VIM high) [9, 17, 40]. However, comparing
primary normal breast tissues (n = 12) with established
normal mammary epithelial cell lines, like HME I
(CRL-4010) and HME II, MCF10A (CRL-10317) and 10 F
(CRL-10318), Keller et al. conclude that these particular
cell lines do not retain the cellular diversity found in
human breast tissues, but appear to be enriched for
differentiation states that represent a minority of breast
tissues [9]. These findings suggest that only assemblies
of cell lines representing multiple cell types can be
used to model the cellular heterogeneity of tissues. Con-
sidering the most well-known established normal and
tumor breast cell lines for research studies, almost all
cell lines resulted in only one of the existing cell type
lineages (Table 3).
Fig. 7 Three-dimensional collagen invasion assays and quantification of cell phenotypes of invasive inflammatory ductal carcinoma (IFDUC)1
mammary epithelial cells (MEC) and mesenchymal cells (MES) incubated with conditioned medium (CM) from different adipose-derived stem cell
(ADSC)-differentiated adipocyte stages. IFDUC1-MEC and IFDUC1-MES cells were incubated with CM from ADSC-IFDUC1 and ADSC-normal mammary
cells (NORMA)4 during adipocyte differentiation at the time points 7, 14 and 21 days to test the influence on invasion for 72 h. Y-axis represents
total number of invaded IFDUC1-MEC cells (invaded cells/cm2); X-axis represents ADSC-CM for control (−− = no CM), and CM at 7, 14 and
21 days; gray bar represents CM from ADSC-IFDUC1 and black bar from ADSC-NORMA4. Directly below three CM dilutions (1:10, 1:20 and 1:30)
were tested and correspond with specific days (a). Examples of IFDUC1-MEC cells on the collagen surface (top) and invaded mesenchymal or
amoeboid phenotypes below the collagen surface (middle and bottom), supporting epithelial to mesenchymal transition (EMT) or epithelial to
amoeboid transition; bar = 50 μm (b). Y-axis represents total number of invaded IFDUC1-MES cells (invaded cells/cm2); X-axis represents ADSC-CM for
control (−−= no CM), and CM at 7, 14 and 21 days; gray bar represents CM from ADSC-IFDUC1 and black bar from ADSC-NORMA4. Directly below three
CM dilutions (1:10, 1:20 and 1:30) were tested and correspond with specific days (c, d). IFDUC1-MES cells on the collagen surface (left) and from the
same field invaded cells below the collagen surface; invaded cells are out of focus (left panels) but become clear when focusing below the surface
(right panels). Bar = 50 μm (e)
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Fig. 8 Three-dimensional culture of breast mesenchymal cells for tissue engineering purposes. a Phase contrast microscope image shows the
two melt electrospinning writing poly(ε-caprolactone) (PCL) scaffolds, PCL-1 (one layer of fibers) and PCL-20 (20 layers of fibers) at cell seeding of
the normal (NORMA)2 mesenchymal cell (MES) cell line and then consecutively at 6 and 18 days of growth. Note that no growth occurred on
PCL-1 throughout the 18-day period. b Confocal microscope image shows NORMA2 MES after 18 days of growth. Image represents an overlay of
43 z-stack sections (each step 1.43 μm) equaling 61.49 μm. Green represents the WGA Alexa 488 fluorescent cellular membrane and the red the
DRAQ5 (633 nm)-stained nuclei. Blue arrow indicates the PCL scaffold overlaid with the bright field channel. White arrow indicates an area with
ongoing cell growth, which originally initiated along the fibers. Bar = 200 μm
Table 2 A short overview of the most common breast cancer cell lines and their origin
Cell line (ATCC) Origin Carcinoma/normal Clinic-pathology
MCF-7 (HTB-22) pleural effusion adenocarcinoma luminal A
T47D (HTB-133) pleural effusion ductal carcinoma luminal A (ER+, Her2–)
MDA-MB-134 (HTB-23) pleural effusion ductal carcinoma epithelial
MDA-MB-231 (HTB-26) pleural effusion adenocarcinoma Claudin low (ER–)
MDA-MB-436 (HTB-130) pleural effusion adenocarcinoma pleomorphic and multinucleated
MDA-MB-453 (HTB-131) pericardial effusion metastatic carcinoma epithelial
MDA-MB-468 (HTB-132) pleural effusion adenocarcinoma basal (ER–, EGFR++)
CAMA-1 (HTB-21) pleural effusion adenocarcinoma epithelial
SK-BR-3 (HTB-30) pleural effusion adenocarcinoma Her2+ (ER–)
HCC1428 (CRL-2327) pleural effusion adenocarcinoma epithelial (ER+, Her2–)
SUM149PT breast inflammatory carcinoma basal B (ER-, PR–)
SUM190PT breast inflammatory carcinoma luminal (ER–, PR–, Her2+)
BT-20 (HTB-19) breast ductal carcinoma epithelial (ER–, EGFR++)
BT-157 (HTB-122) breast ductal carcinoma mesenchymal (ER–)
BT-474 (HTB-20) breast ducts ductal carcinoma luminal B (ER+, Her2+)
Hs578T (HTB-126) breast carcinoma luminal A (ER–)
HCC1954 (CRL-2338) breast ducts ductal carcinoma epithelial (ER-, HER2++)
HCC1143 (CRL-2321) breast ducts ductal carcinoma epithelial (ER–)
MCF10A (CRL-10317) breast normal epithelial adherent
MCF10F (CRL-10318) breast (see MCF10A) normal epithelial floating
hTERT-HME1 (CRL-4010) breast normal epithelial
The origin, the clinic-pathology and the receptor status are from [3, 68, 69] and information from ATCC (www.atcc.org/). ER estrogen receptor, Her2 human epidermal
growth factor-2
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The conclusion of heterogeneity of normal breast tis-
sues or tumors between individuals (heterologous) and a
patient’s normal tissue and the tumor itself (autologous)
led us to perform simultaneous isolations of MEC, MES
and ADSC from normal breast and tumor tissues from
the same individual. Therefore, our study presented the
opportunity to combine gene expression and protein
analyses from isolated breast cell types and perform a
direct comparison with published gene expression pro-
files of normal and tumor cell lineages. In addition, these
cell types can easily be implemented into specific re-
search applications, such as cell functional or drug as-
says. For example, our functional studies demonstrating
that PCL-20 3D-scaffolds containing 20 fibers (but not
single-strand (or 2.5D) scaffolds [41]) supported adhe-
sion and growth of normal breast MES, have important
future clinical implications, especially for breast cancer
patients. Although, more studies are needed one could
envision that using such 3D-printed scaffolds for re-
growing normal breast tissue ex vivo for possible later im-
plantation, has translation applications for the expanding
field of regenerative medicine [14, 42–44].
Comparing the four published normal breast cell line-
ages (luminal (1 and 2) epithelial, basal-like epithelial
and mesenchymal cells) gene/protein expression levels
with our normal and breast tumor cell lines assisted us
further to confirm cell lineages (Table 3). Interestingly,
we interpret that NORMA1 and NORMA2 MEC primary
cell lines resembled luminal 1 epithelial cells, whereas
NORMA3 and NORMA4 resembled luminal 2 epithelial
cells. Additionally, we predict that the IFDUC1 MEC line
has a very high conformity of gene expression (EPCAM,
CD49f, MUC1, KRT8/18/14, ACTA1 and VIM) to the
basal-like epithelial cell lineage (Table 3). However, ex-
pression of CD24, which is normally expressed in luminal
epithelial cells, was 2-fold higher in the IFDUC1 MEC
line, thus, was in contrast [9]. Other researchers also
showed that breast tumors express CD44 and CD24 but
are very heterogeneous among different tumors and also
within the tumor [45]. The latter analysis also found a
CD44+/CD24- phenotype as the most common in the
basal-like subgroup with ER-/PR-/Her2-/KRT5/14+ and in
BRCA1 hereditary tumors. MEC cells of IFDUC1, derived
from a tumor characterized as ER+/PR+/Her2+ and non-
BRCA1 hereditary were both CD44+ and CD24+. In
addition, KRT19 expression representing luminal cells was
negative for MEC of IFDUC1, whereas KRT5 expression
representing basal-like cells was positive in MEC of
IFDUC1. On the other hand, CD10 expression, represent-
ing a basal, bi-potent and myoepithelial cell phenotype
was also highly expressed in MEC of IFDUC1. Thus, the
KRT14+, CD49 high, CD10 high and MUC1 expression
supports the presence of a high portion of bi-potent pro-
genitors in the IFDUC1 MEC primary cell line. Addition-
ally, our findings of CD34+/CD45+ IFDUC1 MEC further
support more undifferentiated tumor cells [46].
Analyzing IFDUC1 MES and ADSC primary cell lines
with the expression signature of the four main cell line-
ages, especially the mesenchymal lineage, we found par-
tial similarities with CD49f, CD24, KRT8, 14 and 18 and
VIM (Table 3). Importantly, the elevated levels of VIM
in IFDUC1 and TRIDUC1 MES and ADSC primary cell
lines supports an invasive potential [47], but could also
reflect breast progenitor cells with a bilinear (glandular
and myoepithelial) differentiation potential [48]. Our
finding that IFDUC1 MES cells additionally expressed
significantly higher levels of SNAI1 and MMP2 along
with a high invasion capability (mean of 1400 invaded
cells per cm2 in 3D collagen matrices) further corrobo-
rates a high invasive phenotype for MES cells isolated
from a patient with an inflammatory breast tumor.
Taken together, the three isolated cell lineages MEC,
MES and ADSC from IFDUC1 reflect the heterogeneity
normally found in tumors and confirm the need to
Table 3 Primary cells confirm the heterogeneity of the tissue





luminal 1 high – + + high high – – low
luminal 2 high + + + high high – – +
basal-like low + – – low low + high high








































For isolated primary cells the lower/higher values correspond to the mean of normal mammary cells (NORMA)1-4 for mammary epithelial cells (MEC),
mesenchymal cells (MES) or adipose-derived stem cells (ADSC). Fold-changes (×) represent lower, equal or higher expression of invasive inflammatory ductal
carcinoma (IFDUC)1 cell lines compared to NORMA1-4 mean values
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establish different cell lines from one tissue to represent
its entirety.
There are approximately 0.6 × 106 ADSC per gram of
breast tissue total, and nearly 6 % of these cells are ex-
pected to be adherent and highly proliferative [49]. It is
well-known that these cells cannot be characterized on
the basis of one single cell surface marker and therefore
a large variety of positive and negative markers are used
for the characterization of ADSC in different studies
(reviewed in [50]). In 2006 the International Society for
Cellular Therapy (ISCT) developed the minimal criteria
for defining multipotent mesenchymal stromal cells [51]:
(a) adherence to plastic, (b) expression of CD105, CD73,
CD90, absence of CD45, CD34, CD14 or CD11b, CD79α
or CD19 and HLA-DR, and (c) multipotent differenti-
ation potential (adipogenic, chondrogenic, osteogenic).
In the present study, isolated ADSC from NORMA1-4
fulfill these criteria, where we observed high expression
of CD105, CD73 and CD90 in ADSC compared to the
other primary cell types and the absence of CD14,
CD19, CD45 and HLA-DR. However, CD34 expression
was generally greater but did differ among the patients.
While the criteria of the ISCT were reported in a
range of publications to have been applied for the
characterization of ADSC, others doubt the applicability,
because of the expression of CD34 in early passages of
ADSC [52]. In an analysis by Baer et al. in ADSC from 16
patients there was high variability in the expression profile
of CD36 and CD34, probably due to the age, body mass
index, ethnicity or medical history of the donors [53].
While some markers increase rapidly after plating, such as
CD29, CD44, CD49d, CD73, CD90, CD105 and CD151,
others, such as CD31 and CD45, decrease. The adipocyte
marker CD36 is often used for distinguishing mesenchy-
mal stem cells from bone marrow and adipose tissue;
we observed high expression in all four of our normal
and in one breast tumor ADSC primary cell lines [54].
Furthermore, we found that the stem cell markers
CD29 and CD44 [55–57] were expressed in NORMA1
ADSC MEC and MES but not significantly differently.
Only some ADSC will lose CD34 expression with in-
creasing culture time, while others maintain it for at
least 10–20 weeks [57]. Suga et al. suggested that loss
of CD34 expression can be seen as a physiological
process of maturation and thus, correlates with replica-
tive capacity or the differentiation potential of ADSC
[58]. In this present study we support the idea that the
significant higher expression of known endothelial
markers CD34 and PDGFRB noted on both normal and
tumor ADSC could be linked with the potential of
ADSC to differentiate into an endothelial-like lineage,
as discussed below. Furthermore, the highest expression
of PDGFRB noted in ADSC TRIDUC1, could verify
the overall worse prognosis of this cancer type, due
to the finding that high stromal PDGFRB expression
is associated with poor prognosis among patients with
breast cancer [59].
Our findings that both IFDUC1 and TRIDUC1 ADSC
lines had lower levels of the marker genes (CD105,
CD73, CD90, CD44, CD106) when compared with
NORMA1-4, supports a link with impaired tumor ADSC
differentiation into osteogenic and chondrogenic lineages.
This suggests that the tumor environment may negatively
influence the ability of the ADSC to differentiate into
these two lineages. On the other hand, our findings that
both IFDUC1 and TRIDUC1 ADSC differentiated into
significantly more complete endothelial-like capillary tube
structures as compared with NORMA1-4 demonstrates
that cultured breast ADSC also have an angiogenesis
potential, similar to freshly isolated and non-adherent
ADSC from non-breast subcutaneous liposuction, which
differentiate in vitro into vascular endothelial cells, vascu-
lar smooth muscle cells and cardiomyocytes [60]. Thus,
breast tumor ADSC play a role in vascularization within
the tumor environment.
It has been noted that normal breast ADSC can be in-
fluenced by tumor factors [61, 62]. For example, breast
ADSC differentiates into a myofibroblastic phenotype
following incubation with CM or with isolated exosomes
from breast tumor cell lines, implicating the transform-
ing growth factor beta signaling pathway [61, 62]. Recent
findings showed that tumor-surrounding adipose tissue
has a major impact on breast cancer progression, following
activation of the adipocytes (so-called cancer-associated
adipocytes) through tumor cells [63]. For example, local
tumor cell invasion occurs early and is closely associated
with white adipose tissue consisting of progenitor and
mature adipocytes [64]. Co-culture systems using heterol-
ogous primary human ADSC (from lipo-aspiration and
breast) with immortalized breast tumor cell lines have
demonstrated increased tumor proliferation, migration,
invasion, EMT and secretion of different factors, e.g.,
inflammatory cytokines (IL-6, IL-8) and matrix metallo-
proteinases (MMPs) [65, 66]. Our autologous and heterol-
ogous co-cultures involving primary tumor ADSC, MEC
and MES (IFDUC1) and NORMA4 ADSC implies im-
portant aspects of the breast tumor environment.
Tumor-associated ADSC exhibit increased plasticity
towards adipocyte differentiation, which has a direct
significant effect, inducing 3D invasion of tumor MEC via
an EMT and amoeboid cells. Our data support the idea
that tumor MEC invasion was induced by CM-adipokine
factors from both early and mature adipocytes, but inter-
estingly, had no effect on tumor MES. Furthermore,
IFDUC1-positive CD34 ADSC could be a contributing
metastatic factor as CD34+ ADSC were shown to induce
a metastatic shift of breast cancer cell lines in a mouse
model [67]. Last, CM-adipokines from NORMA4 ADSC
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differentiating into adipocytes induced invasion of tumor
MEC, but to a lower degree than tumor ADSC. These
findings further point to a possible negative impact of
ADSC on residual breast cancer cells in patients who re-
ceive AFT for esthetic purposes.
Conclusion
In the present study we successfully isolated three differ-
ent cell phenotypes from human primary normal and
tumor breast tissue. We could establish a molecular sig-
nature for MEC, MES and ADSC and propose that only
the ensemble of all cells can represent the tissue or
tumor adequately. As commonly used breast cell lines
only represent specific cell types or differentiation states,
we propose to use assemblies of different cell lines from
the same patient.
Tumor-associated ADSC have an impaired plasticity
towards chondrogenic and osteogenic differentiation,
but an increased adipogenic and endothelial-like differ-
entiation, supporting the idea of a stimulus on invasion
and angiogenesis in the tumor environment. Co-
culturing of isolated autologous and heterologous pri-
mary cell lines could help us to understand gene expres-
sion, differentiation, invasion, hormone and inhibitor/
drug interactions of control versus tumor breast tissue
in vitro that are important for tumor biology and regen-
erative medicine.
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Additional file 1: Primer sequences. (DOCX 18 kb)
Additional file 2: Gene expression of stem cell and hematopoietic
markers in cell isolates. Mammary epithelial cell (MEC), adipose-derived stem
cell (ADSC) and mesenchymal cell (MES) primary cell lines all from the same
patients (four normal (NORMA1-4) and two breast tumor primary cell lines
are indicated). a-f Expression results of positive stem cell markers
CD105, CD73, CD90, CD36, CD29, CD44 and vimentin (VIM) are shown
in four NORMA1-4 and two breast tumor (invasive inflammatory ductal
carcinoma (IFDUC)1, triple-negative ductal carcinoma (TRIDUC)1) different
primary cell lines using real-time PCR (*p ≤0.05). g-l Hematopoietic markers,
CD14, CD19, CD34, CD45 and HLA-DR are shown from peripheral blood cells
(PBC)/blood endothelial cells (BEC), four NORMA1-4 and two breast tumor
(IFDUC1, TRIDUC1) primary cell lines using real-time PCR (*p ≤0.05).
(PPTX 135 kb)
Additional file 3: Gene expression of invasive and mesenchymal
markers in cell isolates. Mammary epithelial cell (MEC), adipose-derived
stem cell (ADSC) and mesenchymal cell (MES) primary cell lines all from
the same patients (four normal (NORMA1-4) and two breast tumor primary
cell lines (invasive inflammatory ductal carcinoma (IFDUC)1, triple-negative
ductal carcinoma (TRIDUC)1)) are indicated. Expression results using real-time
PCR of genes involved in invasion, MMP2, MMP9 and SNAI1 and markers of
the mesenchymal phenotype, N-cadherin (CDH2) and cadherin11
(CDH11) (*p ≤0.05). (PPTX 114 kb)
Additional file 4: Gene expression of typical epithelial cell markers in
cell isolates. Mammary epithelial cell (MEC), adipose-derived stem cell
(ADSC) and mesenchymal cell (MES) primary cell lines all from the same
patients (four normal (NORMA1-4) and the invasive inflammatory ductal
carcinoma (IFDUC)1 breast tumor primary cell line) are indicated.
Expression results are shown for a range of typical markers for
characterization of epithelial cells, the proliferation marker MKI67 and
markers of basal myoepithelial mammary cells (ACTA1, ACTA2, CNN1, CD10)
using real-time PCR (*p ≤0.05). (PPTX 132 kb)
Additional file 5: Endothelial-like differentiation of adipose-derived stem
cells (ADSC) into capillary structures. Endothelial-like differentiation was
quantified 5 h after seeding ADSC on Matrigel®. a X axis represents the
tube length in mm for each capillary side cell structure. b X axis represents
the number of completely closed capillary loop structures. c X axis
represents the area in mm2 for completely closed and open capillary
structures. a-c Y axis represents the origin of the ADSC (triple-negative
ductal carcinoma (TRIDUC)1, invasive inflammatory ductal carcinoma
(IFDUC)1 or normal breast (NORMA)4). Quantification was performed in three
wells (total area 0.125 cm2/well). (PPTX 52 kb)
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